PacBio (PACB) Q4 2024 Earnings Disappoint, Revenue Misses Estimates
PacBio’s Q4 2024 revenue missed estimates, declining 32.8% year-over-year to $39.22 million. The genomics company reported a larger-than-expected loss per share, raising concerns about its near-term performance.
PacBio (PACB) Q4 2024 Earnings Disappoint, Revenue Misses Estimates Read More »